AzTrials
AzTrials

Pain SyndromeEarly Phase 1NCT06377839

Pain After Removal of Mandibular Third Molars With or Without Advanced Platelet-rich Fibrin

A Early Phase 1 study testing Advanced platelet-rich fibrin in the ekstraction socket in people with Pain Syndrome, run by Aalborg University Hospital at 1 site in Denmark.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Pain is the most common complication following surgical removal of an impacted mandibular third molar. Several risk factors may increase the intensity and duration of pain following removal of mandibular third molars. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Pain Syndrome
What is being tested?
Advanced platelet-rich fibrin in the ekstraction socket
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
80 participants
Where
1 siteDenmark
Study dates
10 Jan 2024to 1 Dec 2025
Phase
Early Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Age ≥ 18 years.
  • Presence of a semi- or fully impacted mandibular third molar.
  • Indication for surgical removal of mandibular third molar.

Who cannot join

  • Patients suffering from chronic pain syndrome.
  • Patients in need of daily analgetic.
  • Pregnancy.
  • Psychiatric problems or unrealistic expectations.

Trial locations and contacts

1 site in 1 country.

Denmark1 site, 1 recruiting
  • Department of Oral and Maxillofacial surgery, Aalborg University Hospital

    Aalborg, North Denmark, 9000

    Thomas Starch-Jensen, Professor, +45 23266370, thomas.jensen@rn.dk

    Recruiting

Other trials in Denmark

About this study

Official title: Assessment of Chronic Pain Predictors Following Surgical Removal of Mandibular Third Molars

Pain is the most common complication following surgical removal of an impacted mandibular third molar. Several risk factors may increase the intensity and duration of pain following removal of mandibular third molars. Acute postoperative pain can transcript into postoperative chronic pain without an explainable reason or a specific risk factor. The use of advanced platelet-rich fibrin in the extraction socket following surgical removal of mandibular third molar have diminished the intensity and duration of acute postoperative pain and facilitated improved wound healing. The objective of the present study is therefore to identified specific risk factors and predictors for developing postoperative chronic pain following surgical removal of mandibular third molars with or without advanced platelet-rich fibrin applied in the extraction socket using epigenetic modulation.

Read the detailed description

Pain is the most common complication following surgical removal of an impacted mandibular third molar (SRM3). Acute postoperative pain (APP) following SRM3 is a normal physiological response to the tissue damage and usually treated sufficiently by paracetamol, non-steroidal anti-inflammatory drugs, or opioids. Increasing age, gender, smoking habit, length of surgery, type of anesthesia, intraoperative complications, surgeon's experience, and contamination of the surgical wound are well-known risk factors that affects the intensity and duration of APP. However, APP can transcript into postoperative chronic pain (PCP) without an explainable reason or a specific risk factor. Moreover, specific predictors for development of PCP following SRM3 is currently not sufficiently elucidated.

PCP is defined as pain lasting for two months or more after surgery, when other causes of pain are excluded. The characteristics and intensity of PCP varies among individuals and specific factors for developing PCP has not yet been clearly elucidated. PCP leads to severe functional limitations and impaired oral health-related quality of life (OHRQoL). The presence of pain prior to surgery as well as the intensity and duration of APP are considered as critical predictors for developing PCP. Various pharmacological and preventive strategies have therefore been proposed to minimize the risk of APP following SRM3 including modification of the surgical technique, sufficient intra- and postoperative pain control as well as preoperative psychological intervention focusing on the psychosocial and cognitive risk factors. Moreover, risk factors, such as genetic and epigenetic modifications have also been associated with APP and PCP. Among epigenetic modifications, non-coding RNAs have shown to be associated with the development of PCP. However, clarification of factors that specifically influence the development of PCP following SRM3 remains unknown.

Advanced platelet-rich fibrin (APRF) is a centrifuged fibrin matrix composed of concentrated growth factors, platelet cytokines, and blood cells, which possesses the ability to stimulate wound healing and tissue regeneration. Manufacturing of APRF from blood samples and application of APRF in the extraction socket following SRM3 have diminished the intensity and duration of APP and facilitated improved wound healing, as reported in systematic reviews and meta-analyses. Application of APRF in the extraction socket following SRM3 possess therefore the ability to minimize the risk of developing PCP due to a shorter period of APP.

The objective of the present study is therefore to identified specific predictors for developing PCP following SRM3. Eighty patients with an impacted mandibular third molar will be randomly allocated to SRM3 with or without application of APRF in the extraction socket. A standardized postoperative pain-management regime will be applied following SRM3. Blood samples (80mL) will be obtained intraoperative and one week postoperatively for all included patients. The investigated non-coding RNAs in the blood of participants will be used to assess their association with pain sensitivity and risk of developing PCP. Self-administrated questionnaires and visual analogue scale (VAS) will be used to correlate the results of the of non-coding RNA dysregulation with the duration and intensity of postoperative pain, social and working isolation, physical appearance, eating and speaking ability, diet variations, sleep impairment, and discomfort after one week, one month, and one year, respectively. The Modified Dental Anxiety Scale is used to measure preoperatively dental anxiety. OHRQoL is evaluated by self-administrated questionnaires obtained preoperatively and compared with postoperative assessment after one week, one month, and one year. The primary outcome measure is intensity and duration of postoperative pain following SRM3 with or without application of APRF in the extraction socket. These results will be correlated with alteration in non-coding RNAs expression to identified possible predictors for developing PCP. The results will be published in international peer-reviewed journals as well as presented at congresses.

Conditions
Pain Syndrome
Being tested
Advanced platelet-rich fibrin in the ekstraction socket
Keywords
Pain, surgery, quality of life,
Medical subject headings
Somatoform Disorders, Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Advanced platelet-rich fibrin in the ekstraction socketBiological

    Advanced platelet-rich fibrin is a centrifuged fibrin matrix composed of concentrated growth factors, platelet cytokines, and blood cells, which possesses the ability to stimulate wound healing and tissue regeneration. Advanced platelet-rich fibrin is manufacturing from a blood sample.

Study groups in NCT06377839
Study groupRoleWhat they receive
With advanced platelet-rich fibrin in the ekstraction socketActive comparatorRight or left side of the mandible
Receives: Biological: Advanced platelet-rich fibrin in the ekstraction socket
Without advanced platelet-rich fibrin in the ekstraction socketPlacebo comparatorRight or left side of the mandible
Receives: Biological: Advanced platelet-rich fibrin in the ekstraction socket

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Assessment of postoperative pain by using Visual Analoque scale

    Measurements of pain using Visual Analogue Scale (0 is no pain and 100 is the worst pain), so lower score is a better outcome

    Measured: Postoperative (15 days)

Secondary outcomes (1)
  1. Assessment of quality of life

    Questionnaire for assessment of quality of life

    Measured: Pre- and postoperative (1-year)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Apr 2024
  2. Study start10 Jan 2024
  3. Primary completion17 Apr 2024
  4. Study completion1 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomized controlled trial
Masking
Single blind
Who is masked
Participant
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06377839
Sponsor's protocol ID
N-20230048
Status last verified
Apr 2024
First submitted
9 Apr 2024
Last updated
22 Apr 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing Advanced platelet-rich fibrin in the ekstraction socket in people with Pain Syndrome, run by Aalborg University Hospital at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 22 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Assessment of postoperative pain by using Visual Analoque scale (time frame: Postoperative (15 days)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in